Literature DB >> 10606894

Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis.

S Kamihira1, Y Yamada, M Tomonaga, K Sugahara, K Tsuruda.   

Abstract

The Fas signalling system probably plays a critical role in the natural and chemotherapeutic cell death machinery, suggesting that aberrant Fas expression is involved in growth control of tumours. The membrane isoform (mFas) is a 45 kD cell surface protein containing a single transmembrane region, and induces apoptosis in normal or tumour cells, whereas the soluble isoform (sFas) lacks the transmembrane domain due to alternative splicing of the transcript and is thought to block Fas-mediated apoptosis. To clarify the clinical roles of expression of these two Fas isoforms in adult T-cell leukaemia (ATL), we investigated the levels of the Fas isoforms in 81 patients with ATL. The expression patterns of the Fas isoforms were heterogenous, and there was no significant correlation between mFas and sFas levels: 10/81 cases were negative for mFas and had high serum sFas levels, whereas the remaining 71 cases were positive for mFas and had various levels of expression of the two Fas isoforms. Irrespective of the status of mFas expression in leukaemic cells, the mRNAs encoding these isoforms were always detectable, indicating the potential for protein translation. Although mFas expressed on freshly isolated ATL cells could iduce apoptosis in vitro, positive versus negative mFas status was not associated with any clinical aspects of ATL, whereas the sFas level was strongly correlated with clinical parameters such as serum LDH activity, tumour burden, serum soluble IL-2R level, hypercalcaemia and prognosis. These results suggest that the ratio of Fas isoforms varies, and high expression of the sFas protein and message reflects the malignant behaviour of ATL and is an independent risk factor for the prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606894     DOI: 10.1046/j.1365-2141.1999.01792.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.

Authors:  Samaneh Boroumand-Noughabi; Hamid Reza Sima; Kamran Ghaffarzadehgan; Mostafa Jafarzadeh; Hamid Reza Raziee; Hanieh Hosseinnezhad; Omeed Moaven; Mohammad Taghi Rajabi-Mashhadi; Amir Abbas Azarian; Mojtaba Mashhadinejad; Jalil Tavakkol-Afshari
Journal:  BMC Cancer       Date:  2010-06-10       Impact factor: 4.430

2.  OX40 signaling renders adult T-cell leukemia cells resistant to Fas-induced apoptosis.

Authors:  Akane Kunitomi; Toshiyuki Hori; Michiyuki Maeda; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

3.  A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma.

Authors:  Takahiro Maeda; Kenn Murata; Takuya Fukushima; Kazuyuki Sugahara; Kazuto Tsuruda; Masanobu Anami; Yasuyuki Onimaru; Kunihiro Tsukasaki; Masao Tomonaga; Ryouzou Moriuchi; Hiroo Hasegawa; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

4.  Possible attenuation of fas-mediated signaling by dominant expression of caspase-8 aberrant isoform in adult T-cell leukemia cells.

Authors:  Kazuyuki Sugahara; Tomomi Hayashi; Natsuko Dateki; Yoichi Hirakata; Hitomi Harasawa; Masao Tomonaga; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

5.  Clinical and oncological significance of aberrant Fas (APO-1/CD95) isoform expression in adult T-cell leukemia.

Authors:  S Kamihira; Y Yamada; T Maeda
Journal:  Indian J Clin Biochem       Date:  2000-08

Review 6.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

7.  Up-regulation of Fas (CD95) expression in tumour cells in vivo.

Authors:  Naama Peshes-Yaloz; Dalia Rosen; Paul M Sondel; Peter H Krammer; Gideon Berke
Journal:  Immunology       Date:  2007-04       Impact factor: 7.397

8.  Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis.

Authors:  Maude Gabriel; Yves Delforge; Adeline Deward; Yvette Habraken; Benoit Hennuy; Jacques Piette; Roscoe Klinck; Benoit Chabot; Alain Colige; Charles Lambert
Journal:  BMC Cancer       Date:  2015-04-07       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.